Clostridium difficile infection is an emerging and often difficult-to-treat iatrogenic complication. Recent data suggest that tigecycline, a novel antibiotic with broad-spectrum antibacterial activity, can be used successfully to treat patients with severe Clostridium difficile infection. We report a 70-year-old man who developed severe Clostridium difficile infection, was admitted to the intensive care unit and eventually succumbed to complications of his illness despite receiving tigecycline for approximately three weeks in combination with vancomycin, metronidazole and intravenous immunoglobulin. Additionally, we discuss the unique challenges that emerged during tigecycline treatment, such as the development of Proteus mirabilis bacteraemia and of colonisation with Acinetobacter baumannii resistant to tigecycline. Finally, we review data on other cases reported in the medical literature. Even though tigecycline looks promising for the treatment of Clostridium difficile infection, we urge caution against its indiscriminate use for off label indications.
Clostridium difficile infection (CDI) is an iatrogenic complication of antibiotic use with a spectrum of clinical presentations ranging from mild diarrhoea to life-threatening pseudomembranous colitis 1 . Its incidence, severity and associated mortality have increased dramatically during the past decade, partly due to the emergence of hypervirulent strains and the difficulty of delivering the mainstays of treatment, metronidazole or vancomycin, to the colon by the oral route in the presence of ileus 1 . These facts have prompted researchers to seek better antibiotic and non-antibiotic approaches to the management of this disease.
Recently, the successful treatment of four patients with severe refractory CDI with intravenous tigecycline was reported 2 . We present our negative experience with the management of a similar case and briefly discuss the positive and negative aspects of the use of tigecycline for the treatment of CDI.
CASE HISTORY
A 70-year-old-man with known coronary artery disease was diagnosed with squamous cell laryngeal cancer and underwent laryngectomy, tracheostomy and gastrostomy. His hospital stay was complicated by nosocomial pneumonia (diagnosed on day eight, treated with piperacillin/tazobactam) and pulmonary embolism (on day 36).
On hospital day 46, he developed diarrhoea which was initially attributed to intolerance of the enteral feeding formula. During the following days, he complained of fever and diffuse abdominal pain while physical examination disclosed decreased bowel sounds and prominent anasarca. Meropenem was started on day 50 for a gastrostomy site infection secondary to Enterobacter cloacae. The diagnosis of CDI was established on day 53 by means of a toxin enzyme immunoassay, while a computed tomography scan of the abdomen on the same day showed mural thickening of the rectosigmoid. Enteral feeding was discontinued and the patient was placed on total parenteral nutrition. Treatment with vancomycin (125 mg administered four times per day per gastrostomy) and metronidazole (500 mg administered intravenously four times per day) was also started on day 53. On day 56, meropenem was replaced by intravenous colistin (polymyxin) for the treatment of the gastrostomy site infection with the aim of eliminating an agent that exerts strong selective pressure on the colonic microflora. Due to uncertainty about whether vancomycin was reaching the colon, retention vancomycin enemas administered twice a day were added on day 58. The patient's clinical condition continued to deteriorate: over a period of eight days, his white blood cell count rose from 12.5 to 31×10 9 /l, platelet count decreased from 300 to 85×10 9 /l and creatinine increased from 70.7 to 186.6 µmol/l. Severe hypoalbuminaemia (1.5 g/l) and raised blood lactate levels (3 to 4 mmol/l) were also present.
On hospital day 60, and for unclear reasons, the patient was found pulseless and apnoeic in his bed. Cardiopulmonary resuscitation was successful and the patient was transferred to the intensive care unit (ICu) sedated, mechanically ventilated via his tracheostomy but hypotensive and requiring vasopressor support. Haematological examination showed renal failure (creatinine 203 µmol/l) and hyperlactataemia (2.4 mmol/l), a white blood cell count of 21.1×10 9 /l and platelet count 27×10 9 /l. Intravenous tigecycline and immunoglobulin (400 mg/kg) were added to the antibiotic regimen. Continuous venovenous haemodiafiltration was started and stress-dose steroids were administered. After a brief period of stabilisation, the clinical picture continued to deteriorate further. Specifically, the pseudo-membranous colitis symptoms did not subside, bowel sounds remained consistently absent, high gastric residuals and/or diarrhoeal episodes were noted on a regular basis and enteral feeding could not be successfully re-instituted. A colectomy was considered during the first week of ICu stay but the patient was considered still too unstable by the surgical consultants to undergo this major intervention. It should be noted that a repeat computed tomography of the abdomen on day 72 -after approximately two weeks of tigecycline treatment -showed marked wall thickening of the colon with prominent 'accordion' sign.
On day 75, the patient was in septic shock secondary to Proteus mirabilis bacteraemia. Coagulation abnormalities, direct hyperbilirubinaemia and elevation of transaminases had been noted on hospital day 70 without focal pathology in the right upper quadrant ultrasound. On day 78, tigecycline and metronidazole were discontinued due to the hepatic dysfunction while meropenem/gentamicin were started, according to the antibiogram, for the treatment of Proteus bacteraemia, and vancomycin was administered for the management of CDI. Over the next few days the patient's condition continued to worsen and despite full supportive care and the addition of empirical treatment with daptomycin and caspofungin, he died of refractory septic shock and multiple organ failure on hospital day 85.
DISCuSSIOn
We describe our negative experience with the use of tigecycline in a patient with severe CDI. The index case followed the typical pattern for this disease: advanced age, comorbid conditions, prolonged hospital stay, multiple courses of broadspectrum antibiotics for intercurrent infections and delayed diagnosis 3, 4 . Of interest, upon ICu admission the patient had all the risk factors for severe Clostridium difficile-associated disease that were recently shown to be significant in a study of 336 inpatients with a positive faecal C. difficile toxin: age >70 years, maximum white blood cell count >20×10 9 /l, maximum creatinine level >176.8 µmol/l and minimum albumin level <25 g/l and a computed tomography scan of the abdomen showing colorectal inflammation 5 . Due to the severity of the clinical presentation, he received a combination of vancomycin (per gastrostomy and in retention enemas) with intravenous metronidazole 6 . He was also treated with intravenous immunoglobulin despite its unproven efficacy 7 and tigecycline.
Even though vancomycin and metronidazole are the 'workhorses' in the management of CDI, therapeutic failures and relapses are common. Therefore a number of alternative treatments are often instituted: antibiotics such as rifaximin, ramoplanin and nitazoxanide, faecal transplantation, probiotics, vaccination, immunotherapy and toxin-binding agents such as cholestyramine and tolevamer 8 . unfortunately, these alternatives are neither widely available nor practicable (i.e. faecal transplants) or they have been studied mostly in the setting of a relapse or mild/moderate disease and not in the treatment of severe, refractory infections.
Tigecycline, a semisynthetic derivative of minocycline, is the first glycylcycline antibiotic available for clinical use 9 . It possesses broad-spectrum activity against most gram-positive and gramnegative aerobic and anaerobic bacteria, including multi-drug resistant strains 10 . It was approved by the u.S. Food and Drug Administration in 2005 and by the European Medicines Agency in 2006 for the treatment of complicated intra-abdominal and skin and skin structure infections. Tigecycline is highly active against vegetative C. difficile (MIC 90 0.032 to 0.12 mg/l) while, at least in healthy adult volunteers, its mean faecal concentration after a week of administration is 6.0 mg/kg, far exceeding tigecycline's MIC for C. difficile 1 . In addition, despite its inhibition of bowel microflora, it does not promote spore germination or toxin production by epidemic C. difficile strains 12 . An extensive search of all completed phase II (n=4) and phase III (n=9) clinical trial databases (so far only in abstract form) revealed only five possible C. difficile infections among 2402 tigecycline recipients, a frequency similar to that seen with the comparator antibiotics 13 .
The accumulating in vitro and clinical trial data which suggest that tigecycline is associated with a relatively low risk of inducing CDI and a dearth of clearly effective agents for the treatment of severe refractory CDI, besides metronidazole and vancomycin, led to the use of tigecycline in this setting. In a recently published study, Herpers et al described four patients with severe refractory CDI who were successfully treated with tigecycline 2 .
Our brief report raises some issues that need further discussion, especially since its findings are contradictory with Herpers' report. First, one might question the potential link between the ultimately unfavourable outcome in our patient and the prior tigecycline use. Despite the inherent difficulty in establishing causality between specific interventions or intercurrent illnesses and outcomes in complex ICu cases, we believe that the lack of significant clinical, laboratory and radiologic improvement of the CDI after a reasonable period of tigecycline treatment and the development of Proteus mirabilis bacteraemia played an important role in the therapeutic failure. Specifically, we cannot exclude the possibility that the discontinuation of tigecycline/metronidazole on day 78 worsened CDI, however, this was not probably the determining factor given that: 1) tigecycline had already been administered for 18 days; 2) intravenous metronidazole was not expected to achieve high intraluminal concentrations; and 3) vancomycin, the mainstay of CDI treatment in severely ill patients, was continued. Second, in light of the favourable outcomes achieved with the use of tigecycline in Herpers' report 2 , potential explanations for its failure in our case need to be carefully explored. It is possible that our patient was sicker in part due to the delay of diagnosis. not only was he older than three of the patients in Herpers' report, but he also required continuous renal replacement therapy for the whole period of his ICu stay, while no mention is made in Herpers' study about the need for renal replacement therapy, even though all those patients developed renal failure. Of note, even though the pharmacokinetic profile of tigecycline is generally considered to remain unaffected by severe renal impairment or end-stage renal disease, including subjects receiving haemodialysis 14 , there are no formal guidelines regarding its dosing in patients requiring continuous renal replacement therapy 15 .
Third, since we did not measure faecal tigecycline concentration nor perform culture or typing of the C. difficile strain, we cannot exclude the possibility that individual pharmacokinetics or strain virulence were responsible for the fatal outcome. We also cannot exclude a potential antagonism between tigecycline and vancomycin/metronidazole regarding the treatment of CDI because no data are available. However, tigecycline is considered to exhibit antagonism extremely rarely in vitro and no antagonism in vivo when it is a part of a combination regimen 16 . Fourth, the fact that our patient continued to receive antimicrobials for other nosocomial infections while being treated for his CDI might have increased the likelihood of treatment failure 17 while colectomy might have been pursued more aggressively despite the potential risks.
Fifth, we consider it worth emphasising that the development of Proteus mirabilis bacteraemia, a preterminal event in our patient's ICu stay, was related to the use of tigecycline. We have previously reported that superinfections from pathogens with inherent resistance to tigecycline (Proteus spp., Providencia spp., Morganella spp. and Pseudomonas aeruginosa) are common when tigecycline is used for the treatment of infections from multi-drug resistant gram-negative pathogens 18 . Of note, four days before the patient's death, an endotracheal aspirate culture performed routinely in our ICu for surveillance purposes yielded Acinetobacter baumannii resistant to tigecycline (MIC, 8 µg/ml). Finally, it should be noted that the hepatic dysfunction and coagulopathy experienced by our patient are among the adverse events we have previously observed in patients receiving tigecycline 18 .
In conclusion, even though tigecycline is not expected to be universally effective, it seems to be the most promising, widely available antibiotic for the treatment of severe Clostridium difficile infection. However, the vast ecologic pressure it exerts on the host's microflora and its yet to be fully determined side-effect profile should encourage researchers to collect more formal comparative data and continue exploring alternative strategies and investigational, including non-antimicrobial, agents. Especially in hospital settings like ours which face an epidemic of gram-negative bacteria producing extendedspectrum ß-lactamases and carbapenemases, we express extreme concern that the indiscriminate
